GH

Guardant Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

152.21
+2.74
+1.83%
Opening 11:08 04/21 EDT
OPEN
149.99
PREV CLOSE
149.47
HIGH
152.48
LOW
147.25
VOLUME
225.43K
TURNOVER
--
52 WEEK HIGH
181.07
52 WEEK LOW
71.41
MARKET CAP
15.29B
P/E (TTM)
-58.9896
1D
5D
1M
3M
1Y
5Y
Press Release: Guardant Health to Report First Quarter Financial Results on May 6, 2021
Dow Jones · 04/12 20:05
How a Simple Blood Test Could Reduce Cancer Deaths
Liquid biopsies and genomic sequencing that track cancer-related DNA have spawned start-ups and produced eye-popping projections on Wall Street. The diagnostic technology is cutting edge, and the industry is very young.
Barrons.com · 04/12 12:26
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at the AACR Virtual Annual Meeting I, April 10-15, 2021, highlighting the use of the company’s proprietary blood tests to advance p...
Business Wire · 04/10 13:35
DJ FTC's Challenge of Illumina Is a Boost for Rivals in Cancer Test Race -- Barrons.com
Dow Jones · 04/06 19:56
DJ Illumina's Gene-Sequencing Business Is Rebounding. It's Girding for an Antitrust Fight. -- Barrons.com
Dow Jones · 04/06 16:39
Bear of the Day: Guardant Health (GH)
Bear of the Day: Guardant Health (GH)
Zacks · 04/06 16:11
Is Guardant Health (NASDAQ:GH) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Simply Wall St. · 04/06 10:05
BRIEF-Guardant Health Receives New York State CLEP Approval For Guardant Reveal Blood Test
reuters.com · 04/01 13:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GH. Analyze the recent business situations of Guardant Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GH stock price target is 177.80 with a high estimate of 195.00 and a low estimate of 145.00.
EPS
Institutional Holdings
Institutions: 541
Institutional Holdings: 91.05M
% Owned: 90.66%
Shares Outstanding: 100.43M
TypeInstitutionsShares
Increased
178
9.90M
New
102
4.77M
Decreased
86
12.22M
Sold Out
26
284.96K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.40%
Pharmaceuticals & Medical Research
+0.90%
Key Executives
Chairman/President/Chief Operating Officer/Director
AmirAli Talasaz
Chief Executive Officer/Director
Helmy Eltoukhy
Chief Financial Officer
DEREK BERTOCCI
Chief Financial Officer
Michael Bell
Chief Information Officer
Kumud Kalia
Other
Michael Wiley
Lead Director/Independent Director
Ian Clark
Director
Vijaya Gadde
Independent Director
Bahija Jallal
Independent Director
Samir Kaul
Independent Director
Stanley Meresman
No Data
About GH
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant360 is a molecular diagnostic test that measures 73 cancer-related genes from circulating tumor deoxyribonucleic acid (ctDNA). Its Guardant360 process includes blood collection, laboratory processing, analysis and reporting. Guardant360 is used for a range of applications, including translational science research and identifying target patient populations, drug development and commercialization post-drug approval.

Webull offers kinds of Guardant Health Inc stock information, including NASDAQ:GH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GH stock methods without spending real money on the virtual paper trading platform.